Role of nociceptor estrogen receptor GPR30 in a rat model of endometriosis pain
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Endometriosis, the most common cause of chronic pelvic pain, is an estrogen-dependent disease in which classic estrogen receptors (ERα, ERβ) play an important role. Although recent evidence suggests that the novel G protein-coupled estrogen receptor (GPR30) also plays a key role in the progression of endometriosis, whether it is also involved in endometriosis pain is still unknown. Here we tested the hypothesis that GPR30 expressed by nociceptors contributes to endometriosis pain. Intramuscular injection of the GPR30 agonists raloxifene or 17β-estradiol produced a fast-onset, persistent, mechanical hyperalgesia at the site of the injection. Intrathecal antisense (AS) oligodeoxynucleotides (ODN), but not mismatch (MM) ODN, targeting mRNA for GPR30 markedly inhibited its protein expression in nociceptors and attenuated the mechanical hyperalgesia induced by local raloxifene or 17β-estradiol. Pretreatment with the GPR30 antagonist G-36 also inhibited the hyperalgesia induced by raloxifene or 17β-estradiol in naive control rats. Surgical implant of autologous uterine tissue onto the gastrocnemius muscle, which induces endometriosis-like lesions, produced local mechanical hyperalgesia. Intrathecal AS, but not MM, ODN targeting GPR30 mRNA reversibly inhibited the mechanical hyperalgesia at the site of endometriotic lesions. Finally, intralesional injection of the GPR30 antagonist G-36 also inhibited the mechanical hyperalgesia at the site of ectopic uterine tissue. We conclude that local GPR30 agonists produce persistent mechanical hyperalgesia in naive female rats, whereas local GPR30 antagonists inhibit mechanical hyperalgesia in a model of endometriosis pain. Thus, GPR30 expressed by nociceptors innervating ectopic uterine lesions might play a major role in endometriosis pain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A transmembrane intracellular estrogen receptor mediates rapid cell signaling
Revankar, C. M., Cimino, D. F., Sklar, L. A., Arterburn, J. B., & Prossnitz, E. R. (2005) · Science · doi:10.1126/science.1106943 · Cited by 2,302 · cited 1×
“More recently, a novel estrogen receptor, the G protein–coupled receptor 30 (GPR30, also called G protein–coupled estrogen receptor 1, GPER1), has been identified [25,49,50].”
BackgroundGiudice, L. C. (2010) · New England Journal of Medicine · doi:10.1056/nejmcp1000274 · Cited by 1,924 · cited 7×
“Endometriosis, a gynecologic disease which affects up to 10% of women of reproductive age, is a major cause of chronic pelvic pain [27].”
BackgroundInfluentialEffects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women
Barrett-Connor, E., Mosca, L., Collins, P., Geiger, M. J., Grady, D., Kornitzer, M., McNabb, M. A., & Wenger, N. K. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062462 · Cited by 1,048
The G-protein-coupled estrogen receptor GPER in health and disease
Prossnitz, E. R., & Barton, M. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.122 · Cited by 925 · cited 1×
“More recently, a novel estrogen receptor, the G protein–coupled receptor 30 (GPR30, also called G protein–coupled estrogen receptor 1, GPER1), has been identified [25,49,50].”
BackgroundAromatase expression in endometriosis.
Noble, L. S., Simpson, E. R., Johns, A., & Bulun, S. E. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550748 · Cited by 566 · cited 2×
“Because ectopic uterine tissue in humans [22,32,35,38,43,44,58] and rats [15] express the enzyme aromatase, which is critical for the synthesis of estrogen [10], locally produced estrogen acting on GPR30 might sensitize nociceptors innervating the endometriosis lesion.”
BackgroundChronic pelvic pain and endometriosis: translational evidence of the relationship and implications
Stratton, P., & Berkley, K. J. (2011) · Human Reproduction Update · doi:10.1093/humupd/dmq050 · Cited by 442 · cited 7×
“Indeed, clinical reports of therapies targeting estrogen are contradictory: on the one hand, combined oral contraceptives containing estrogen can improve endometriosis pain [51,54,56], whereas raloxifene, which blocks some estrogen effects in a tissue-dependent manner, has been reported to markedly shorten the time to…”
BackgroundInfluentialProstaglandin E2 Stimulates Aromatase Expression in Endometriosis-Derived Stromal Cells
Noble, L. S. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.2.600 · Cited by 301
Innervation of ectopic endometrium in a rat model of endometriosis
Berkley, K. J., Dmitrieva, N., Curtis, K. S., & Papka, R. E. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403663101 · Cited by 227 · cited 1×
“Because endometriosis lesions are innervated by nociceptors [4,8,27,54] and produce estrogen [17,43,44], we evaluated the role of GPR30 in endometriosis pain.”
BackgroundSeracchioli, R., Mabrouk, M., Manuzzi, L., Vicenzi, C., Frasca, C., Elmakky, A., & Venturoli, S. (2009) · Human Reproduction · doi:10.1093/humrep/dep259 · Cited by 158
Aromatase expression in endometriotic tissues and cell cultures of patients with endometriosis
Velasco, I. (2006) · Molecular Human Reproduction · doi:10.1093/molehr/gal041 · Cited by 108
Huang, H.-F., Hong, L.-H., Tan, Y., & Sheng, J.-Z. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.027 · Cited by 90
Hyperinnervation in Intestinal Deep Infiltrating Endometriosis
Wang, G., Tokushige, N., Russell, P., Dubinovsky, S., Markham, R., & Fraser, I. S. (2009) · Journal of Minimally Invasive Gynecology · doi:10.1016/j.jmig.2009.07.012 · Cited by 85 · cited 1×
“For instance, histological analysis of endometriosis lesions in humans [40,59] and in animal models [4] has revealed the expression of growth-associated protein-43 (GAP-43) in their innervating nociceptors.”
BackgroundYao, Z., Shen, X., Capodanno, I., Donnelly, M., Fenyk-Melody, J., Hausamann, J., Nunes, C., Strauss, J., & Vakerich, K. (2005) · Journal of Investigative Surgery · doi:10.1080/08941930591004412 · Cited by 60
Comparison of the effects of raloxifene and anastrozole on experimental endometriosis
Altintas, D., Kokcu, A., Kandemir, B., Tosun, M., & Cetinkaya, M. B. (2010) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2010.02.004 · Cited by 57
Two unsuccessful clinical trials on endometriosis and a few lessons learned
Guo, S.-W., & Olive, D. L. (2007) · Gynecologic and Obstetric Investigation · doi:10.1159/000098413 · Cited by 49 · cited 1×
“While a phase II clinical study of the use of fulvestrant for endometriosis launched on 1999 never reported its outcome, another trial using raloxifene had to be stopped due to a significantly unfavorable outcome [29].”
BackgroundEctopic uterine tissue as a chronic pain generator
Alvarez, P., Chen, X., Hendrich, J., Irwin, J. C., Green, P. G., Giudice, L. C., & Levine, J. D. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.08.033 · Cited by 39
Self-citationNew treatment strategies and emerging drugs in endometriosis
Streuli, I., de Ziegler, D., Borghese, B., Santulli, P., Batteux, F., & Chapron, C. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.668885 · Cited by 27 · cited 1×
“…targeting estrogen are somewhat contradictory: on one hand, combined oral contraceptives containing estrogen can improve endometriosis pain [51; 54; 56] whereas raloxifene, which blocks some estrogen effects in a tissue-dependent manner, has been reported to markedly shorten the time to…”
Background
Cited by
Maddern, J., Grundy, L., Castro, J., & Brierley, S. M. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.590823 · Cited by 254
Current and emerging treatment options for endometriosis
Ferrero, S., Evangelisti, G., & Barra, F. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1494154 · Cited by 152
Androgens, oestrogens and endometrium: a fine balance between perfection and pathology
Gibson, D. A., Simitsidellis, I., Collins, F., & Saunders, P. T. K. (2020) · Journal of Endocrinology · doi:10.1530/joe-20-0106 · Cited by 76
A comprehensive review of hormonal and biological therapies for endometriosis: latest developments
Barra, F., Grandi, G., Tantari, M., Scala, C., Facchinetti, F., & Ferrero, S. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1581761 · Cited by 69
A peek into the drug development scenario of endometriosis – A systematic review
Goenka, L., George, M., & Sen, M. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.03.092 · Cited by 37
Metadata
- Authors
- Alvarez, P., Bogen, O., & Levine, J. D.
- Venue
- Pain
- Published
- 2014-12
- Volume
- 155
- Issue
- 12
- Pages
- 2680-2686
- ISSN
- 0304-3959 (ISSN-L)
- OpenAlex
- W2101934635
- Cited by
- 37
- References
- 17
- FWCI
- 3.08
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.